Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Sort descending Date Recommendation Issued
Nucala mepolizumab Eosinophilic granulomatosis with polyangiitis CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Forxiga dapagliflozin Chronic kidney disease CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Emgality galcanezumab Episodic cluster headache CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Clolar clofarabine Acute lymphoblastic leukemia CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Breyanzi lisocabtagene maraleucel Relapsed or refractory large B-cell lymphoma Pending
TBC fruquintinib Metastatic colorectal cancer (mCRC) Pending
Onivyde Nanoliposomal Irinotecan Cancelled
Cyramza Ramucirumab Cancelled
Combigan Ophthalmic Solution Brimonidine tartrate/timolol maleate Glaucoma List with clinical criteria and/or conditions Complete
Reyataz Atazanavir HIV infection List in a similar manner to other drugs in class Complete